Studio the economically justifiable price in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy
We are very pleased to share a new publication of which OMAKASE is a co-author t [...]
MCDA methodology in the Farmacia Hospitalaria journal
Today, we are pleased to share with you the publication of our latest work using [...]
Alicia Gil, CEO Omakase Consulting attended a session held in the Spanish National Congress organised by FEDER (Spanish Rare Diseases Organisation)
Alicia Gil, CEO Omakase Consulting attended yesterday a session held in the Span [...]
The new update in the information system BIFIMED from the Spanish Ministry of Health
The Spanish Ministry of Health has updated the information system BIFIMED, an in [...]
Feasibility study to characterize price and reimbursement decision-making criteria for the inclusion of new drugs in the Spanish National Health System
We are very pleased to share the first study characterizing the criteria of the [...]
The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis
Omakase Consulting continues its focus and work on contributing to the generatio [...]
Omakase Consulting keeps growing!
We have opened new offices in #Madrid. We inaugurate this new space with great e [...]
New publication about the incidence and management of patients with methotrexate delayed elimination
We are very pleased to share a new publication of which OMAKASE is a coauthor: a [...]
We are pleased to announce the release of Horizon Scanning 2021 report where Omakase Consulting is working with Orphar-SEFH
Hello network! We are pleased to announce the release of the Horizon Scanning Re [...]
New publication about the socio-economic burden on patients, and their caregivers, suffering from severe thrombocytopenia associated with chronic liver disease (CLD) who undergo invasive procedures in Spain
We are pleased to share a new publication of which OMAKASE is a co-author on a r [...]